Overview
| Candidate | Pre | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
Leronlimab
|
Pre-Clinical Phase completed
|
Phase 1 completed
|
Phase 2 completed
|
Phase 3 in progress
|
Leronlimab (PRO 140)
Leronlimab PRO 140 is a fully humanized monoclonal antibody which is a cellular targeting CCR5 entry antagonist recently acquired from Progenics Pharmaceuticals.